| Recruiting | 3 | 496 | Europe, Japan, US, RoW | Regorafenib in combination with pembrolizumab, Stivarga® (regorafenib), Keytruda® (pembrolizumab), Loco-regional therapy, Convention transarterial chemoembolization (cTACE), Drug-eluting bead transarterial chemoembolization (DEB-TACE), Transarterial Chemoembolization (TACE), Transarterial radioembolization (TARE) | Translational Research in Oncology, Bayer | Carcinoma, Hepatocellular | 10/25 | 04/27 | | |
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC |
|
|
| Not yet recruiting | 2 | 60 | Europe, US | RP3, atezolizumab, bevacizumab | Replimune Inc., Roche Pharma AG | Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 04/27 | 07/27 | | |
| Recruiting | N/A | 1000 | Europe | Physician's choice according to patient's needs. | iOMEDICO AG | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | 12/26 | 12/26 | | |
